Zepbound Switching: How to Transition From or To Other GLP-1/GIP Drugs Safely Zepbound Switching: How to Transition From or To Other Drugs in Class At a glance Drug / Zepbound (tirzepatide), Eli Lilly Drug class / Dual GIP and GLP-1 receptor agonist Approved indication / Chronic weight management in adults with BMI 30, or 27 with one weight-related comorbidity Dosing frequency / Once weekly subcutaneous injection Starting dose / 2.5 mg weekly, escalated every 4 weeks Maximum dose / 15 mg weekly Key trial / SURMOUNT-1 (N=2,539): 20.9% mean body-weight loss at 72 weeks on 15 mg Half-life / Approximately 5 days (supports once-weekly dosing) Common switch scenarios / Semaglutide to tirzepatide, liraglutide to tirzepatide, tirzepatide to oral semaglutide FDA approval date / November 8, 2023 (weight management indication) How Zepbound Works: Mechanism at the Receptor Level Zepbound binds both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor
%20receptor%20agonists%2C%20such%20as%20liraglutide%20(Victoza)%20or%20semaglutide%20(Ozempic)%2C%20be%20stopped%20in%20patients%20with%20type%202%20diabetes%20prior%20to%20elective%20surgery%3F)
The Study Details The average BMI in this trial was 35
Sugary and ultra-processed foods including fizzy drinks, sweets, cakes, and highly refined snacks offer little nutritional value and can cause rapid fluctuations in blood glucose
Energy levels remain stable
You need: adequate lean muscle appropriate fat stores strong bone turnover stable blood sugar efficient digestion and motility low, well-regulated inflammation These arent nice-to-haves
